Trial
NCT03277755
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Hepatic Impairment
Intervention
AL-335 800 mg
Why stopped
Development program of JNJ-4178 was discontinued.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-11